| Literature DB >> 29953616 |
Guobao Chen1, William Bracamonte-Baran1, Nicola L Diny2, Xuezhou Hou2, Monica V Talor1, Kai Fu3, Yue Liu3, Giovanni Davogustto4, Hernan Vasquez4, Heinrich Taegtmeyer4, O Howard Frazier5, Ari Waisman6, Simon J Conway7, Fengyi Wan3,8, Daniela Čiháková1,2.
Abstract
The causative effect of GM-CSF produced by cardiac fibroblasts to development of heart failure has not been shown. We identified the pathological GM-CSF-producing cardiac fibroblast subset and the specific deletion of IL-17A signaling to these cells attenuated cardiac inflammation and heart failure. We describe here the CD45- CD31- CD29+ mEF-SK4+ PDGFRα+ Sca-1+ periostin+ (Sca-1+ ) cardiac fibroblast subset as the main GM-CSF producer in both experimental autoimmune myocarditis and myocardial infarction mouse models. Specific ablation of IL-17A signaling to Sca-1+ periostin+ cardiac fibroblasts (PostnCre Il17rafl/fl ) protected mice from post-infarct heart failure and death. Moreover, PostnCre Il17rafl/fl mice had significantly fewer GM-CSF-producing Sca-1+ cardiac fibroblasts and inflammatory Ly6Chi monocytes in the heart. Sca-1+ cardiac fibroblasts were not only potent GM-CSF producers, but also exhibited plasticity and switched their cytokine production profiles depending on local microenvironments. Moreover, we also found GM-CSF-positive cardiac fibroblasts in cardiac biopsy samples from heart failure patients of myocarditis or ischemic origin. Thus, this is the first identification of a pathological GM-CSF-producing cardiac fibroblast subset in human and mice hearts with myocarditis and ischemic cardiomyopathy. Sca-1+ cardiac fibroblasts direct the type of immune cells infiltrating the heart during cardiac inflammation and drive the development of heart failure.Entities:
Keywords: Fibroblasts; GM-CSF; Heart failure; IL-17; Myocarditis
Mesh:
Substances:
Year: 2018 PMID: 29953616 PMCID: PMC6696927 DOI: 10.1002/eji.201847583
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532